Anaptysbio (ANAB) Long-Term Investments (2017 - 2025)

Anaptysbio has reported Long-Term Investments for 9 years, with the latest figure at $7.7 million in Q3 2025.

• For the quarter ending Q3 2025, Long-Term Investments fell 72.42% year-over-year to $7.7 million; the trailing twelve-month figure through Sep 2025 stood at $7.7 million (down 72.42% YoY), and the FY2024 full-year result was $35.5 million, up 31.24% from the prior year.
• Long-Term Investments for Q3 2025 stood at $7.7 million, down from $28.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $147.5 million in Q3 2022, with the low at $5.5 million in Q2 2021.
• Historically, Long-Term Investments has averaged $54.1 million across 5 years, with a median of $40.2 million in 2023.
• Annual changes were most pronounced in 2021 — Long-Term Investments slumped 85.95% — and 2022, when it surged 2270.26%.
• Anaptysbio's Long-Term Investments stood at $67.1 million in 2021, then jumped by 113.03% to $142.9 million in 2022, then sank by 81.09% to $27.0 million in 2023, then jumped by 31.24% to $35.5 million in 2024, then plunged by 78.3% to $7.7 million in 2025.
• The last three Long-Term Investments figures came in at $7.7 million (Q3 2025), $28.0 million (Q2 2025), and $43.0 million (Q1 2025), per Business Quant data.